# Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension

Study · id `cardio:ct-nct00993109` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT00993109](<https://clinicaltrials.gov/study/NCT00993109>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT00993109

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

## Technical summary

Registry record NCT00993109. Randomized; no masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2011-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 360 participants (enrolled count; ClinicalTrials.gov record NCT00993109, source copy `cardio:ctgov-nct00993109-2014-06-05`, retrieved 2026-10-26)
- Start date: 2010-02 (registry gives no type) (ClinicalTrials.gov record NCT00993109, source copy `cardio:ctgov-nct00993109-2014-06-05`, retrieved 2026-10-26)
- Primary completion: 2011-05 (actual) (ClinicalTrials.gov record NCT00993109, source copy `cardio:ctgov-nct00993109-2014-06-05`, retrieved 2026-10-26)
- Completion: 2011-05 (actual) (ClinicalTrials.gov record NCT00993109, source copy `cardio:ctgov-nct00993109-2014-06-05`, retrieved 2026-10-26)
- Countries: China; South Korea (ClinicalTrials.gov record NCT00993109, source copy `cardio:ctgov-nct00993109-2014-06-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct00993109-2014-06-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension
- Condition: Hypertension
- Intervention (Drug): Adalat (Nifedipine, BAYA1040)
- Intervention (Drug): Diovan (Valsartan)
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Improved blood pressure control with nifedipine GITS/valsartan combination versus high-dose valsartan monotherapy in mild-to-moderate hypertensive patients from Asia: results from the ADVISE study, a randomized trial (`cardio:pubmed-23134522`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 83301d16a3d1d1fbf69cc99a4202c54381792cefeff76a0a6d0c8891a0aded2e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
